13908-32-2

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-CHLOROETHYL)-N'-(4-FLUOROPHENYL)UREA is used as a building block for the synthesis of various drugs and compounds, contributing to the development of new therapeutic agents.
Used in Medicinal Chemistry:
N-(2-CHLOROETHYL)-N'-(4-FLUOROPHENYL)UREA is used as a valuable tool in medicinal chemistry for the exploration of its potential applications in the treatment of various diseases and conditions.
Used in Drug Discovery:
N-(2-CHLOROETHYL)-N'-(4-FLUOROPHENYL)UREA is used in drug discovery processes to identify and optimize its potential as a therapeutic agent, leveraging its unique chemical structure for the development of novel treatments.

Upstream product

• 1195-45-5 para-fluorophenyl isocyanate 
• 689-98-5 chloroethylamine 
• 870-24-6 2-chloroethanamine hydrochloride 
• 1943-83-5 2-chloroethyl isothiocyanate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 13909-17-6 C₉H₉ClFN₃O₂ 
• 53159-75-4 1-(4-fluorophenyl)-2-oxo-tetrahydroimidazole 
• 1596360-60-9 methyl 6-[[3-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596360-40-5 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-83-6 9H-fluoren-9-ylmethyl N-[(5S)-5-cyano-5-[[6-[[3-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]pentyl]carbamate 

Relevant academic research and scientific papers

Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is

2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS

Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

New substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with α2-adrenoceptor antagonist activity

The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at α2-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent α2-adrenoceptor antagonists with good selectivity versus α1-adrenergic and D2-dopamine receptors. Particular emphasis is given to compound 33g which displays potent α2-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.